Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does treatment with 17 α-hydroxyprogesterone caproate increase the risk of gestational diabetes mellitus?

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 130–131 (2008)Cite this article

boxed-textRebarber A et al. (2007) Increased incidence of gestational diabetes in women receiving prophylactic 17 α-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 30: 2277–2280

Women receiving 17 α-hydroxyprogesterone caproate for the prevention of preterm labor might be at increased risk of developing gestational diabetes mellitus and should be screened accordingly

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Petrou S (2005) The economic consequences of preterm birth during the first 10 years of life. BJOG 112 (Suppl 1): 10–15

    Article  PubMed  Google Scholar 

  2. da Fonseca EB et al. (2003) Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188: 419–424

    Article  CAS  PubMed  Google Scholar 

  3. Meis PJ et al. (2003) Prevention of recurrent preterm delivery by 17 α-hydroxyprogesterone caproate. N Eng J Med 348: 2379–2385

    Article  CAS  Google Scholar 

  4. González-Quintero VH et al. (2007) The impact of glycemic control on neonatal outcome in singleton pregnancies complicated by gestational diabetes. Diabetes Care 30: 467–470

    Article  PubMed  Google Scholar 

  5. Crowther CA et al. (2005) Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 352: 2477–2486

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. DJ Tuffnell is a Professor of Obstetrics and Gynaecology and S McClean is a Clinical Fellow in the Department of Obstetrics and Gynaecology, Bradford Hospitals NHS Trust, Bradford, UK.,

    Derek J Tuffnell & Serwaa McClean

Authors
  1. Derek J Tuffnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serwaa McClean
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Derek J Tuffnell.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tuffnell, D., McClean, S. Does treatment with 17 α-hydroxyprogesterone caproate increase the risk of gestational diabetes mellitus?. Nat Rev Endocrinol 4, 130–131 (2008). https://doi.org/10.1038/ncpendmet0721

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0721

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing